证券代码：688606 证券简称：奥泰生物 公告编号：2026-012 杭州奥泰生物技术股份有限公司 2025年度业绩快报公告 一、2025年度主要财务数据和指标 单位：人民币万元 ■ 注：1.本报告期初数同法定披露的上年年末数一致。 2.以上财务数据及指标以合并报表数据填制，但未经审计，最终结果请以公司2025年年度报告为准。数 据若有尾差，为四舍五入所致。 二、经营业绩和财务状况情况说明 （一）报告期的经营情况、财务状况及影响经营业绩的主要因素 报告期内，公司实现营业总收入91,130.05万元，较上年同期增长5.16%；实现归属于母公司所有者的净 利润21,828.01万元，较上年同期下降27.83%；实现归属于母公司所有者的扣除非经常性损益的净利润 15,524.62万元，较上年同期下降34.64%。报告期末，公司财务状况良好，总资产额424,862.06万元，较 本报告期初增长1.50%；归属于母公司的所有者权益394,449.65万元，较本报告期初增长1.57%。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 ...

证券日报网讯 2月27日，奥泰生物发布公告称，公司2025年度实现营业总收入91130.05万元，同比增长 5.16%；归属于母公司所有者的净利润为21828.01万元。 （文章来源：证券日报） ...

格隆汇2月27日丨奥泰生物(688606.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入9.11亿 元，较上年同期增长5.16%；实现归属于母公司所有者的净利润2.18亿元，较上年同期下降27.83%；实 现归属于母公司所有者的扣除非经常性损益的净利润1.55亿元，较上年同期下降34.64%。 影响经营业绩的主要原因：（1）公司持续发挥在研发创新、产品质量、客户服务等多个方面的综合竞 争优势，进一步拓宽销售渠道并增加客户销售量；（2）公司持续加大对新技术平台的研发投入，并重 点开展国内外市场和产品注册等拓展工作，致使公司研发及销售成本同比增加；(3)此外，美国政府加 征关税导致公司营业成本上升，加上美元汇率波动引起汇兑损失、利息收入降低及资产折旧摊销增加等 多方面原因导致利润同比下滑。 ...

格隆汇2月27日丨奥泰生物(688606.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入9.11亿 元，较上年同期增长5.16%；实现归属于母公司所有者的净利润2.18亿元，较上年同期下降27.83%；实 现归属于母公司所有者的扣除非经常性损益的净利润1.55亿元，较上年同期下降34.64%。 影响经营业绩的主要原因：（1）公司持续发挥在研发创新、产品质量、客户服务等多个方面的综合竞 争优势，进一步拓宽销售渠道并增加客户销售量；（2）公司持续加大对新技术平台的研发投入，并重 点开展国内外市场和产品注册等拓展工作，致使公司研发及销售成本同比增加；(3)此外，美国政府加 征关税导致公司营业成本上升，加上美元汇率波动引起汇兑损失、利息收入降低及资产折旧摊销增加等 多方面原因导致利润同比下滑。 ...

证券代码：688606 证券简称：奥泰生物 公告编号：2026-012 杭州奥泰生物技术股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计， 具体数据以杭州奥泰生物技术股份有限公司（以下简称"公司"）2025年年度报 告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：人民币万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度 | | --- | --- | --- | --- | | | | | （％） | | 营业总收入 | 91,130.05 | 86,658.30 | 5.16 | | 营业利润 | 24,974.78 | 34,551.79 | -27.72 | | 利润总额 | 24,911.44 | 34,771.34 | -28.36 | | 归属于母公司所有 者的净利润 | 21,828.01 | 30,247.20 | -27.83 | | 归属于母公司所有 者 ...

南财智讯2月27日电，奥泰生物发布2025年度业绩快报，报告期内公司实现营业收入9.11亿元，同比增 长5.16%；归属于上市公司股东的净利润2.18亿元，同比减少27.83%；基本每股收益2.75元，同比减少 28.01%。 ...

奥泰生物发布业绩快报，2025年度公司实现营业总收入9.11亿元，较上年同期增长5.16%；实现归属于 母公司所有者的净利润2.18亿元，较上年同期下降27.83%；实现归属于母公司所有者的扣除非经常性损 益的净利润1.55亿元，较上年同期下降34.64%。 ...

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Project Progress - The company announced the completion of the "Marketing Network Center Construction Project" and the "Hangzhou Aokai Biological Annual Production of 400 Million In Vitro Diagnostic Reagents R&D Center Construction Project," resulting in approximately 210 million yuan of surplus raised funds to permanently supplement working capital, optimizing fund efficiency [2] Fund Movements - On January 21, 2026, the company's board approved a share repurchase plan, intending to use 100 to 200 million yuan of over-raised funds for a buyback at a price not exceeding 85 yuan per share, aimed at reducing registered capital. This plan was approved at the extraordinary shareholders' meeting on February 6, 2026, and will be executed within the next 12 months [3] Strategic Advancement - The announcement also disclosed the 2026 annual routine related party transaction plan, totaling 51.3 million yuan, focusing on high-margin areas such as respiratory multiplex testing and pet diagnostics to address industry transformation [4]

Core Viewpoint - The company plans to repurchase its shares using funds raised from its initial public offering, with the aim of reducing its registered capital and enhancing shareholder value [2][36]. Group 1: Share Repurchase Details - The total amount for the share repurchase will be no less than RMB 100 million and no more than RMB 200 million [2]. - The repurchase price will not exceed RMB 85 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [2][14]. - The repurchase will be conducted through centralized bidding [3][9]. Group 2: Implementation Timeline - The repurchase period will last for 12 months from the date the shareholders' meeting approves the plan [4][10]. - If the repurchase amount reaches the upper limit, the plan will be completed early [11]. Group 3: Purpose and Funding - The purpose of the repurchase is to maintain shareholder interests and enhance investor confidence based on the company's future development prospects [7][36]. - The funds for the repurchase will come from the excess funds raised during the company's initial public offering [15][36]. Group 4: Shareholder and Management Plans - As of the announcement date, there are no plans for share reductions by directors, senior management, or major shareholders in the next three to six months [4][18]. - The proposal for the share repurchase was initiated by the company's controlling shareholder and chairman, Gao Fei [19][36]. Group 5: Legal and Regulatory Compliance - The company has complied with relevant laws and regulations regarding the share repurchase process, including notifying creditors as required [7][37]. - The repurchased shares will be legally canceled, thereby reducing the registered capital [20][21].